newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Reuters
Japan's Eisai (4523.T), opens new tab will licence Shanghai Henlius Biotech's (2696.HK) lung cancer drug Hansizhuang.
Eisai will license Henlius's lung cancer drug Hansizhuang, paying $75 million upfront.
KEY POINTS
Henlius could receive up to $313.34 million in milestone payments from Eisai under this deal.
Eisai's license covers development, manufacturing, and commercialization of Hansizhuang as an injection in Japan.
Henlius has business partnerships to commercialize Hansizhuang in over 100 countries and regions.
SHANGHAI, Feb 5 (Reuters) - Japan's Eisai (4523.T), opens new tab will licence Shanghai Henlius Biotech's (2696.HK), opens new tab lung cancer drug Hansizhuang, paying $75 million upfront and up to $313.34 million more if milestones are met, the Chinese drugmaker said on Thursday.
The deal is the latest overseas licensing agreement for the drug, approved in markets including China and the European Union, which for Henlius brought in sales, opens new tab of .6 billion yuan in the first half of 2025.
Sign up here.
Henlius has entered into business partnerships for commercialising Hansizhuang in more than 100 countries and regions, it said in a filing, opens new tab.
Under the agreement with Eisai, it is eligible to receive up to $80.01 million in payments tied to regulatory milestones, and up to $233.33 million for sales-related milestones, plus additional royalties based on annual net sales.
The agreement covers the development, manufacturing and commercialisation of the drug as an injection. Eisai has been granted a license in Japan for oncology indications.
Reporting by Andrew Silver in Shanghai, Editing by Louise Heavens